XW04367
Introduction Central Vein to New Technology Group 7 with Terlipressin, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 4 Central Vein |
| Approach | 3 Percutaneous |
| Device | 6 Terlipressin |
| Qualifier | 7 New Technology Group 7 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Central Vein
Central veins, including the vena cavae and other large-caliber vessels near the heart, provide access for substances that require rapid dilution, higher infusion volumes, or delivery closer to central circulation than a peripheral vein allows. Introduction procedures coded here under New Technology reflect administration of a novel agent through this central route, which is often chosen when a substance is irritating to smaller vessels or needs to reach systemic circulation quickly and at high concentration. Central venous access typically requires a dedicated catheter placed under imaging or landmark guidance, and the procedure carries different risks, including central line infection, compared with peripheral administration. Coding accuracy depends on documenting that central rather than peripheral venous access was used for the introduced substance.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Terlipressin
Terlipressin is a synthetic vasopressin analog administered to reduce portal pressure and splanchnic blood flow, primarily indicated for hepatorenal syndrome with rapid reduction in kidney function. It acts on vasopressin receptors to cause vasoconstriction, distinguishing it from other cardiovascular or coagulation-directed New Technology agents in this list, such as coagulation factor Xa, inactivated, which works through hemostatic rather than vasopressor mechanisms.
Qualifier: New Technology Group 7
As a qualifier value, Group 7 marks a code as belonging to the set of new technologies approved for use in the 2020-2021 fiscal year, a period that included a notable expansion of infectious-disease-related add-on codes. The label does not describe what the technology does; that detail sits in the table and other axis values. It is distinguished from adjoining groups solely by its approval-year cohort.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.